Highlights newsletter 2 This newsletter presents you the following key sessions: 1. VIDEO-INTERVIEW: Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, presents the results of a Phase 1 Study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis 2. Significantly improved outcomes with combination of brentuximab vedotin and AVD compared to standard ABVD as frontline therapy for previously untreated advanced Hodgkin lymphoma 3. Consistent benefit of lenalidomide maintenance therapy in both transplant-eligible and transplant ineligible multiple myeloma patients, irrespective of the cytogenetic risk 4. Durable and high responses with the CD19 targeting CAR T-cell therapy tisagenlecleucel in adults with relapsed/ refractory diffuse large B-cell lymphoma 5. The anti-CCR4 antibody mogamulizumab delays disease progression compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma 6. Adding daratumumab to VMP doubles the progression-free survival in patients with newly diagnosed, transplant ineligible multiple myeloma